Lab
Southern Ohio Medical Center
Southern Ohio Medical Center was paid $145.26M by Medicaid between Jan 2018 and Dec 2024, across 648 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 27% of everything it billed.
33Billing provider infoSOUTHERN OHIO MEDICAL CENTER
PORTSMOUTH, OH 45662
PORTSMOUTH, OH 45662
33aNPI1053342816assigned 07/06/2006
33bProvider typeClinical Medical Laboratory
28Total paid$145.26M
24GClaims3,493,646
24DCodes billed648
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Ohio
Rank by total paid#3 of 116
Median peer was paid$313K
This provider vs. median465×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 321,214 | $11.02M | |
| 2019 | 358,027 | $12.50M | |
| 2020 | 284,627 | $13.49M | |
| 2021 | 368,475 | $17.88M | |
| 2022 | 484,790 | $22.36M | |
| 2023 | 908,986 | $36.33M | |
| 2024incomplete | 767,527 | $31.68M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 27% | 387,130 | 304,809 | $38.84M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 12% | 189,285 | 173,395 | $17.78M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 10% | 136,656 | 126,832 | $14.95M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 4.2% | 48,606 | 42,292 | $6.03M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.8% | 30,180 | 26,031 | $4.03M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 1.8% | 23,316 | 21,801 | $2.58M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.7% | 9,954 | 8,636 | $2.47M |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.5% | 66,921 | 59,390 | $2.24M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.5% | 25,734 | 24,102 | $2.17M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.5% | 6,305 | 5,438 | $2.11M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.4% | 36,231 | 7,917 | $2.07M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.3% | 64,485 | 57,294 | $1.86M |
636 more codes
| 96361 | Intravenous infusion, hydration; each additional hour | 1.2% | 8,877 | $1.79M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.0% | 4,503 | $1.51M |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 56,291 | $1.44M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 11,348 | $1.32M |
| 80053 | Comprehensive metabolic panel | <1% | 74,429 | $1.28M |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 11,235 | $1.10M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 3,089 | $1.01M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 3,941 | $927K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 4,433 | $908K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 11,150 | $882K |
| 20610 | <1% | 7,571 | $872K | |
| G0378 | Hospital observation service, per hour | <1% | 9,466 | $870K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 38,257 | $844K |
| 0223U | <1% | 4,337 | $843K | |
| 93458 | <1% | 717 | $839K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 11,391 | $797K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 58,987 | $774K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 6,714 | $670K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 7,641 | $624K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 913 | $588K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 85,126 | $587K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 35,631 | $584K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 73,896 | $578K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 136,577 | $578K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,467 | $558K |
| 36415 | Collection of venous blood by venipuncture | <1% | 248,555 | $549K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 18,113 | $519K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 5,081 | $468K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 56,310 | $448K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 19,201 | $437K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 886 | $421K |
| 80061 | Lipid panel | <1% | 39,669 | $402K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,320 | $399K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,962 | $388K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,068 | $376K |
| 59025 | Fetal non-stress test | <1% | 2,371 | $373K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,993 | $367K |
| 82607 | <1% | 22,837 | $359K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 35,412 | $350K |
| 95886 | <1% | 1,665 | $343K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 5,430 | $343K |
| 76830 | Ultrasound, transvaginal | <1% | 3,453 | $333K |
| 90839 | <1% | 2,506 | $316K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 3,011 | $291K |
| 71045 | Radiologic examination, chest; single view | <1% | 32,477 | $272K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 2,877 | $271K |
| 93975 | <1% | 1,650 | $242K | |
| 95811 | <1% | 381 | $240K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 5,070 | $235K |
| 11045 | <1% | 691 | $232K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 3,374 | $230K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,337 | $228K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 28,447 | $211K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 18,686 | $207K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 14,364 | $202K |
| 78431 | <1% | 371 | $202K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,634 | $201K |
| 84439 | <1% | 21,152 | $201K | |
| 71271 | <1% | 1,237 | $201K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 14,164 | $189K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 36,608 | $182K |
| 71250 | <1% | 1,637 | $181K | |
| 75574 | <1% | 589 | $179K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 658 | $174K |
| 97161 | <1% | 2,586 | $173K | |
| 93017 | <1% | 2,142 | $170K | |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 173 | $167K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 10,362 | $167K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,067 | $161K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 340 | $161K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 811 | $159K |
| J3490 | Unclassified drugs | <1% | 15,052 | $159K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 325 | $157K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 15,210 | $154K |
| 83605 | <1% | 31,390 | $150K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,580 | $150K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 49,151 | $147K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 547 | $145K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 22,374 | $142K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 884 | $138K |
| 80076 | <1% | 36,703 | $136K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 3,556 | $133K |
| 84484 | <1% | 28,710 | $127K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 670 | $124K |
| 76536 | <1% | 1,177 | $122K | |
| 64615 | <1% | 512 | $122K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 21,273 | $122K |
| 76641 | <1% | 1,227 | $116K | |
| C1776 | Joint device (implantable) | <1% | 147 | $115K |
| 72131 | <1% | 1,344 | $115K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 542 | $115K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,425 | $110K |
| 94060 | <1% | 1,190 | $107K | |
| 87481 | <1% | 8,796 | $105K | |
| 73221 | <1% | 408 | $105K | |
| 81003 | <1% | 51,994 | $105K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 10,244 | $104K |
| 87522 | Neg quan hep c or qual rna | <1% | 3,763 | $104K |
| 73630 | <1% | 4,912 | $103K | |
| 84145 | <1% | 14,275 | $100K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 5,280 | $91K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 205 | $91K |
| 87625 | <1% | 5,029 | $91K | |
| 12001 | <1% | 591 | $91K | |
| 93970 | <1% | 673 | $90K | |
| 87653 | <1% | 5,232 | $89K | |
| 74178 | <1% | 257 | $88K | |
| 83540 | <1% | 11,857 | $88K | |
| 87902 | <1% | 637 | $86K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 9,451 | $83K |
| 80074 | <1% | 5,098 | $83K | |
| 84702 | <1% | 5,692 | $83K | |
| 31575 | <1% | 508 | $82K | |
| 82728 | <1% | 6,749 | $81K | |
| 73030 | <1% | 3,482 | $81K | |
| 58558 | <1% | 91 | $81K | |
| 87040 | <1% | 18,536 | $79K | |
| 87081 | <1% | 7,116 | $78K | |
| 73562 | <1% | 3,320 | $76K | |
| 81596 | <1% | 668 | $75K | |
| 83735 | <1% | 25,047 | $75K | |
| 96376 | <1% | 4,605 | $75K | |
| 97162 | <1% | 1,422 | $73K | |
| 97016 | <1% | 2,280 | $73K | |
| 93971 | <1% | 1,037 | $73K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 1,090 | $73K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,664 | $72K |
| 47562 | <1% | 30 | $71K | |
| 52000 | <1% | 120 | $71K | |
| 84703 | <1% | 15,688 | $69K | |
| 95816 | <1% | 483 | $69K | |
| 73610 | <1% | 3,115 | $69K | |
| 81025 | <1% | 8,347 | $68K | |
| 93356 | <1% | 341 | $65K | |
| 87529 | <1% | 4,824 | $65K | |
| 87511 | <1% | 5,976 | $64K | |
| 94726 | <1% | 1,098 | $63K | |
| 96367 | <1% | 1,512 | $63K | |
| 73130 | <1% | 3,037 | $62K | |
| 20550 | <1% | 470 | $62K | |
| 93880 | <1% | 689 | $61K | |
| 97165 | <1% | 882 | $60K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 209 | $60K |
| 92928 | <1% | 16 | $58K | |
| 93226 | <1% | 532 | $57K | |
| 83525 | <1% | 3,547 | $57K | |
| 72100 | <1% | 1,661 | $56K | |
| 84481 | <1% | 5,122 | $55K | |
| 83550 | <1% | 7,861 | $54K | |
| 82746 | <1% | 5,184 | $53K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 3,010 | $53K |
| 86140 | <1% | 12,322 | $52K | |
| 83880 | <1% | 7,753 | $52K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 18,672 | $51K |
| 86592 | <1% | 2,830 | $51K | |
| 85007 | <1% | 11,637 | $51K | |
| 95913 | <1% | 445 | $51K | |
| 72141 | <1% | 320 | $50K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 697 | $49K |
| 81001 | <1% | 41,079 | $48K | |
| 73560 | <1% | 2,398 | $48K | |
| 70491 | <1% | 158 | $48K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 20,219 | $48K |
| 84144 | <1% | 1,987 | $48K | |
| C1769 | Guide wire | <1% | 1,118 | $47K |
| 86695 | <1% | 2,914 | $47K | |
| 93798 | <1% | 1,655 | $47K | |
| 94729 | <1% | 1,137 | $46K | |
| 93225 | <1% | 564 | $45K | |
| 80081 | <1% | 2,169 | $45K | |
| 94618 | <1% | 609 | $45K | |
| 83655 | <1% | 3,263 | $44K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 618 | $43K |
| 84403 | <1% | 2,829 | $43K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 224 | $43K |
| 85027 | <1% | 12,711 | $43K | |
| 85610 | <1% | 18,221 | $42K | |
| 86696 | <1% | 2,989 | $42K | |
| 73110 | <1% | 2,132 | $41K | |
| 76775 | <1% | 544 | $41K | |
| 86481 | <1% | 819 | $40K | |
| 73502 | <1% | 1,877 | $40K | |
| 97116 | <1% | 1,532 | $39K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 13,488 | $39K |
| 73700 | <1% | 308 | $38K | |
| 70486 | <1% | 533 | $37K | |
| 58661 | <1% | 22 | $37K | |
| J2704 | Injection, propofol, 10 mg | <1% | 12,717 | $37K |
| 87186 | <1% | 6,871 | $36K | |
| 82950 | <1% | 3,327 | $36K | |
| 97113 | <1% | 602 | $36K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,575 | $36K |
| 91200 | <1% | 467 | $35K | |
| 72128 | <1% | 634 | $34K | |
| 92557 | <1% | 508 | $34K | |
| 74018 | <1% | 2,060 | $33K | |
| 82670 | <1% | 1,715 | $33K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 1,009 | $33K |
| 11981 | <1% | 159 | $32K | |
| 95912 | <1% | 261 | $32K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,963 | $32K |
| 90715 | <1% | 1,805 | $31K | |
| 83690 | <1% | 21,331 | $31K | |
| 76981 | <1% | 508 | $30K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 12,879 | $30K |
| 95911 | <1% | 311 | $29K | |
| 90686 | <1% | 1,963 | $29K | |
| 20552 | <1% | 358 | $29K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 199 | $29K |
| 76857 | <1% | 223 | $28K | |
| 72040 | <1% | 730 | $28K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 161 | $28K |
| 84146 | <1% | 2,180 | $28K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 278 | $28K |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | <1% | 389 | $28K |
| 72070 | <1% | 831 | $27K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 581 | $27K |
| 74019 | <1% | 1,172 | $27K | |
| 84402 | <1% | 1,960 | $27K | |
| C1753 | Catheter, intravascular ultrasound | <1% | 336 | $26K |
| 72110 | <1% | 677 | $26K | |
| 86850 | <1% | 1,365 | $26K | |
| 83001 | <1% | 1,832 | $26K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 724 | $26K |
| 36430 | <1% | 244 | $25K | |
| 86038 | <1% | 1,430 | $25K | |
| 82962 | <1% | 13,448 | $25K | |
| 70496 | <1% | 115 | $25K | |
| 96127 | <1% | 676 | $24K | |
| 84153 | <1% | 1,839 | $24K | |
| 10060 | <1% | 148 | $24K | |
| 86900 | <1% | 2,053 | $24K | |
| 77062 | <1% | 763 | $23K | |
| 86376 | <1% | 1,597 | $23K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,307 | $22K |
| 77080 | <1% | 336 | $22K | |
| 87109 | <1% | 1,939 | $22K | |
| 87641 | <1% | 1,398 | $22K | |
| 87631 | <1% | 189 | $21K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,361 | $21K |
| 36416 | <1% | 8,941 | $21K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 315 | $21K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 110 | $21K |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 1,520 | $21K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 14 | $21K |
| 74022 | <1% | 1,006 | $20K | |
| 73564 | <1% | 838 | $20K | |
| 86803 | <1% | 1,427 | $20K | |
| 92978 | <1% | 263 | $20K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 419 | $20K |
| 85652 | <1% | 6,785 | $19K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,831 | $19K |
| 83970 | <1% | 852 | $19K | |
| 84681 | <1% | 1,603 | $19K | |
| 64493 | <1% | 44 | $19K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,161 | $19K |
| 82626 | <1% | 995 | $18K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 6,829 | $18K |
| 70498 | <1% | 168 | $18K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,027 | $18K |
| 72050 | <1% | 320 | $18K | |
| 73080 | <1% | 922 | $18K | |
| 83002 | <1% | 1,398 | $18K | |
| 96368 | <1% | 472 | $18K | |
| 85730 | <1% | 10,428 | $18K | |
| 82043 | <1% | 3,263 | $18K | |
| 11102 | <1% | 40 | $18K | |
| 93922 | <1% | 258 | $18K | |
| 31231 | <1% | 107 | $17K | |
| 86800 | <1% | 1,467 | $17K | |
| 87340 | <1% | 1,177 | $17K | |
| 58563 | <1% | 17 | $17K | |
| 82248 | <1% | 1,887 | $17K | |
| 84207 | <1% | 1,346 | $17K | |
| 87506 | <1% | 152 | $16K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,716 | $16K |
| C1874 | Stent, coated/covered, with delivery system | <1% | 237 | $16K |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 110 | $16K |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | <1% | 16 | $16K |
| 76010 | <1% | 935 | $15K | |
| 69210 | <1% | 1,066 | $15K | |
| 73523 | <1% | 429 | $15K | |
| 86787 | <1% | 823 | $15K | |
| 86694 | <1% | 588 | $15K | |
| 82077 | <1% | 6,133 | $14K | |
| 88142 | <1% | 1,144 | $14K | |
| 87070 | <1% | 3,523 | $14K | |
| 20605 | <1% | 104 | $14K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,269 | $14K |
| 12002 | <1% | 100 | $14K | |
| 76882 | <1% | 130 | $14K | |
| 19081 | <1% | 18 | $13K | |
| 73590 | <1% | 981 | $13K | |
| 17110 | <1% | 91 | $13K | |
| 86706 | <1% | 1,086 | $13K | |
| 77061 | <1% | 418 | $13K | |
| 77066 | Tomosynthesis, mammo | <1% | 733 | $13K |
| 83498 | <1% | 923 | $13K | |
| 76870 | <1% | 342 | $13K | |
| 85018 | <1% | 6,965 | $13K | |
| 58300 | <1% | 88 | $13K | |
| 73090 | <1% | 786 | $12K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,685 | $12K |
| 84100 | <1% | 5,224 | $12K | |
| 11982 | <1% | 57 | $12K | |
| 82533 | <1% | 581 | $12K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,077 | $12K |
| 87071 | <1% | 1,829 | $12K | |
| 82947 | <1% | 2,858 | $12K | |
| 82565 | <1% | 1,956 | $11K | |
| 64721 | <1% | 15 | $11K | |
| 72170 | <1% | 978 | $11K | |
| 82552 | <1% | 2,002 | $11K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 62 | $11K |
| 92567 | <1% | 747 | $10K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,665 | $10K |
| 70544 | <1% | 87 | $10K | |
| 86431 | <1% | 874 | $10K | |
| 72114 | <1% | 244 | $10K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,310 | $10K |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 686 | $10K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,339 | $10K |
| 97010 | <1% | 771 | $9K | |
| 86704 | <1% | 508 | $9K | |
| 62323 | <1% | 12 | $9K | |
| 70480 | <1% | 85 | $9K | |
| 84436 | <1% | 1,038 | $9K | |
| 93299 | <1% | 691 | $9K | |
| 83883 | <1% | 345 | $9K | |
| 85379 | <1% | 3,329 | $9K | |
| 76642 | <1% | 110 | $9K | |
| 36600 | <1% | 1,903 | $9K | |
| 76000 | <1% | 185 | $8K | |
| 82140 | <1% | 1,698 | $8K | |
| 82570 | <1% | 1,292 | $8K | |
| 84480 | <1% | 753 | $8K | |
| 77065 | Tomosynthesis, mammo | <1% | 424 | $8K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 16 | $8K |
| 73140 | <1% | 467 | $8K | |
| 86901 | <1% | 2,024 | $8K | |
| 84550 | <1% | 1,872 | $8K | |
| 52204 | <1% | 17 | $7K | |
| 73620 | <1% | 410 | $7K | |
| 76770 | <1% | 44 | $7K | |
| 82150 | <1% | 3,503 | $7K | |
| 80143 | <1% | 3,826 | $7K | |
| 43450 | <1% | 454 | $7K | |
| 82951 | <1% | 343 | $7K | |
| 77336 | <1% | 113 | $7K | |
| 95012 | <1% | 190 | $7K | |
| 90677 | <1% | 69 | $6K | |
| 84112 | <1% | 217 | $6K | |
| 86200 | <1% | 550 | $6K | |
| 87807 | <1% | 2,675 | $6K | |
| 84425 | <1% | 608 | $6K | |
| 80164 | <1% | 424 | $6K | |
| 71101 | <1% | 476 | $6K | |
| 82977 | <1% | 972 | $6K | |
| 74420 | <1% | 84 | $6K | |
| J0558 | Injection, penicillin g benzathine and penicillin g procaine, 100,000 units | <1% | 58 | $6K |
| 83516 | <1% | 388 | $6K | |
| 36591 | <1% | 1,072 | $6K | |
| 97164 | <1% | 183 | $6K | |
| 82784 | <1% | 664 | $6K | |
| 80179 | <1% | 3,813 | $6K | |
| 82105 | <1% | 557 | $6K | |
| 87205 | <1% | 2,410 | $5K | |
| 80051 | <1% | 436 | $5K | |
| 82803 | <1% | 1,893 | $5K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,329 | $5K |
| 73060 | <1% | 361 | $5K | |
| 73552 | <1% | 342 | $5K | |
| 93571 | <1% | 195 | $5K | |
| 93321 | <1% | 31 | $5K | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 800 | $5K |
| 86364 | <1% | 328 | $5K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 154 | $5K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 11,647 | $5K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,800 | $5K |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 1,138 | $5K |
| 90656 | <1% | 357 | $5K | |
| 83519 | <1% | 167 | $5K | |
| 87184 | <1% | 471 | $5K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,106 | $5K |
| 86255 | <1% | 408 | $4K | |
| 93288 | <1% | 379 | $4K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 311 | $4K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 732 | $4K |
| 80361 | <1% | 507 | $4K | |
| 58301 | <1% | 51 | $4K | |
| 99406 | <1% | 137 | $4K | |
| 84479 | <1% | 586 | $4K | |
| 82952 | <1% | 340 | $4K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,587 | $4K |
| 87077 | <1% | 1,557 | $4K | |
| 70470 | <1% | 16 | $4K | |
| 97597 | <1% | 87 | $4K | |
| 72020 | <1% | 611 | $4K | |
| 82103 | <1% | 303 | $4K | |
| 85520 | <1% | 2,078 | $4K | |
| 82310 | <1% | 719 | $4K | |
| J2791 | Injection, rho(d) immune globulin (human), (rhophylac), intramuscular or intravenous, 100 iu | <1% | 56 | $4K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 2,804 | $4K |
| 83010 | <1% | 554 | $4K | |
| 84156 | <1% | 894 | $4K | |
| 83615 | <1% | 1,147 | $4K | |
| 73120 | <1% | 188 | $4K | |
| 29125 | <1% | 289 | $4K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 666 | $4K |
| 82172 | <1% | 359 | $3K | |
| 57454 | <1% | 12 | $3K | |
| J8501 | Aprepitant, oral, 5 mg | <1% | 260 | $3K |
| 82330 | <1% | 1,634 | $3K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 64 | $3K |
| J2800 | Injection, methocarbamol, up to 10 ml | <1% | 433 | $3K |
| P9047 | Infusion, albumin (human), 25%, 50 ml | <1% | 24 | $3K |
| 83721 | <1% | 495 | $3K | |
| 82375 | <1% | 1,542 | $3K | |
| 84520 | <1% | 891 | $3K | |
| 77002 | <1% | 43 | $3K | |
| 84132 | <1% | 1,845 | $3K | |
| 86003 | <1% | 174 | $3K | |
| 86618 | <1% | 340 | $3K | |
| 86617 | <1% | 362 | $3K | |
| 93325 | <1% | 45 | $3K | |
| 84460 | <1% | 630 | $3K | |
| 80354 | <1% | 505 | $3K | |
| 80348 | <1% | 507 | $3K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 1,333 | $3K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,344 | $3K |
| 87493 | <1% | 201 | $3K | |
| 80346 | <1% | 440 | $3K | |
| 83921 | <1% | 461 | $3K | |
| 84450 | <1% | 515 | $3K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,122 | $3K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 873 | $3K |
| 90837 | Psychotherapy session, about an hour | <1% | 13 | $3K |
| 85014 | <1% | 521 | $3K | |
| 80353 | <1% | 508 | $3K | |
| 80365 | <1% | 491 | $3K | |
| 80358 | <1% | 508 | $3K | |
| 83992 | <1% | 197 | $3K | |
| 82024 | <1% | 74 | $2K | |
| 87210 | <1% | 837 | $2K | |
| 86308 | <1% | 643 | $2K | |
| 73600 | <1% | 167 | $2K | |
| 86923 | <1% | 119 | $2K | |
| 80326 | <1% | 211 | $2K | |
| 64483 | <1% | 18 | $2K | |
| 80321 | <1% | 310 | $2K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 230 | $2K |
| Q9950 | Injection, sulfur hexafluoride lipid microspheres, per ml | <1% | 303 | $2K |
| 82550 | <1% | 201 | $2K | |
| 86665 | <1% | 222 | $2K | |
| 82247 | <1% | 377 | $2K | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 210 | $2K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,372 | $2K |
| 97163 | <1% | 32 | $2K | |
| 84295 | <1% | 1,303 | $2K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 153 | $2K |
| 80355 | <1% | 219 | $2K | |
| 86235 | <1% | 132 | $2K | |
| 80178 | <1% | 159 | $2K | |
| 86141 | <1% | 87 | $2K | |
| C1781 | Mesh (implantable) | <1% | 15 | $2K |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 1,220 | $2K |
| 90461 | <1% | 2,326 | $2K | |
| 88184 | <1% | 16 | $2K | |
| 84445 | <1% | 67 | $2K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 66 | $2K |
| 83050 | <1% | 1,506 | $2K | |
| 86015 | <1% | 132 | $2K | |
| 93799 | <1% | 47 | $2K | |
| 80377 | <1% | 195 | $2K | |
| 80360 | <1% | 197 | $2K | |
| 80337 | <1% | 197 | $2K | |
| 80334 | <1% | 197 | $2K | |
| 80338 | <1% | 197 | $2K | |
| 80331 | <1% | 197 | $2K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 503 | $2K |
| 80373 | <1% | 197 | $2K | |
| 84305 | <1% | 95 | $2K | |
| 80341 | <1% | 197 | $2K | |
| 80370 | <1% | 197 | $2K | |
| 80344 | <1% | 197 | $2K | |
| 73100 | <1% | 86 | $2K | |
| 80366 | <1% | 197 | $2K | |
| 80368 | <1% | 197 | $2K | |
| 80372 | <1% | 197 | $2K | |
| 80367 | <1% | 197 | $2K | |
| 80357 | <1% | 197 | $2K | |
| 80364 | <1% | 197 | $2K | |
| 80359 | <1% | 197 | $2K | |
| 80371 | <1% | 197 | $2K | |
| 90694 | <1% | 191 | $2K | |
| 86225 | <1% | 158 | $2K | |
| 12011 | <1% | 12 | $1K | |
| 87581 | <1% | 272 | $1K | |
| 82040 | <1% | 334 | $1K | |
| 86664 | <1% | 149 | $1K | |
| 82652 | <1% | 137 | $1K | |
| 97166 | <1% | 13 | $1K | |
| 82465 | <1% | 308 | $1K | |
| J2598 | Injection, vasopressin, 1 unit | <1% | 107 | $1K |
| 51798 | <1% | 575 | $1K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 534 | $1K |
| 80362 | <1% | 295 | $1K | |
| 82785 | <1% | 138 | $1K | |
| 73070 | <1% | 66 | $1K | |
| 83521 | <1% | 334 | $1K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 581 | $1K |
| 80349 | <1% | 296 | $1K | |
| 92523 | <1% | 14 | $1K | |
| 80356 | <1% | 294 | $1K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 124 | $1K |
| 80324 | <1% | 279 | $1K | |
| 82272 | <1% | 176 | $1K | |
| 76377 | <1% | 48 | $1K | |
| 87045 | <1% | 87 | $1K | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 179 | $1K |
| 87177 | <1% | 82 | $1K | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 175 | $1K |
| 20553 | <1% | 33 | $1K | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 261 | $1K |
| 72220 | <1% | 26 | $972.43 | |
| 93925 | <1% | 13 | $942.03 | |
| 90674 | <1% | 38 | $921.16 | |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 15 | $902.86 |
| 88185 | <1% | 15 | $872.24 | |
| 85045 | <1% | 413 | $872.02 | |
| A4217 | Sterile water/saline, 500 ml | <1% | 979 | $860.33 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 441 | $849.59 |
| 99195 | <1% | 24 | $819.44 | |
| 86160 | <1% | 84 | $818.61 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 556 | $814.82 |
| 29581 | <1% | 26 | $796.27 | |
| 84482 | <1% | 96 | $781.10 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 291 | $773.14 |
| 80069 | <1% | 81 | $745.67 | |
| 84478 | <1% | 281 | $745.42 | |
| 73000 | <1% | 47 | $727.16 | |
| J7121 | 5% dextrose in lactated ringers infusion, up to 1000 cc | <1% | 189 | $725.14 |
| 72081 | <1% | 13 | $721.37 | |
| 72052 | <1% | 16 | $703.19 | |
| 90653 | <1% | 113 | $701.23 | |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 85 | $675.45 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 572 | $661.53 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 35 | $648.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,144 | $641.05 |
| 11721 | <1% | 58 | $623.53 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 454 | $611.75 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 125 | $598.37 |
| 84165 | <1% | 175 | $572.08 | |
| 80177 | <1% | 46 | $567.91 | |
| 87185 | <1% | 211 | $552.55 | |
| 88304 | <1% | 34 | $530.25 | |
| J0574 | Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine | <1% | 60 | $529.63 |
| 86705 | <1% | 42 | $499.74 | |
| 95249 | <1% | 156 | $474.25 | |
| 80347 | <1% | 67 | $419.82 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 262 | $413.99 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 540 | $411.71 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 304 | $396.10 |
| J2372 | Injection, phenylephrine hydrochloride (biorphen), 20 micrograms | <1% | 1,568 | $390.12 |
| 90678 | <1% | 21 | $389.86 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 888 | $386.63 |
| J1836 | Injection, metronidazole, 10 mg | <1% | 101 | $377.11 |
| J1941 | Injection, furosemide (furoscix), 20 mg | <1% | 64 | $354.77 |
| 80299 | <1% | 24 | $354.72 | |
| 86304 | <1% | 17 | $350.39 | |
| 84155 | <1% | 179 | $349.44 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 66 | $333.68 |
| 83993 | <1% | 14 | $329.78 | |
| 86708 | <1% | 87 | $293.99 | |
| 86709 | <1% | 27 | $293.83 | |
| 86334 | <1% | 27 | $292.37 | |
| 82378 | <1% | 31 | $277.96 | |
| 86666 | <1% | 57 | $251.11 | |
| 90661 | <1% | 19 | $243.36 | |
| 87149 | <1% | 58 | $233.50 | |
| 84154 | <1% | 25 | $233.19 | |
| 87523 | <1% | 14 | $219.69 | |
| 86039 | <1% | 16 | $217.53 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 135 | $216.17 |
| J3535 | Drug administered through a metered dose inhaler | <1% | 216 | $210.25 |
| 82010 | <1% | 141 | $184.17 | |
| 80156 | <1% | 13 | $182.10 | |
| 82274 | <1% | 16 | $171.34 | |
| 86753 | <1% | 39 | $164.48 | |
| 90662 | <1% | 47 | $160.53 | |
| 86008 | <1% | 25 | $160.07 | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 129 | $160.06 |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | <1% | 14 | $159.76 |
| 85347 | <1% | 195 | $139.54 | |
| 64494 | <1% | 44 | $138.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 698 | $124.19 |
| 87075 | <1% | 33 | $112.52 | |
| 90682 | <1% | 17 | $109.86 | |
| 87430 | <1% | 83 | $109.33 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 29 | $108.88 |
| 87338 | <1% | 15 | $92.52 | |
| 84238 | <1% | 13 | $78.90 | |
| J0173 | Injection, epinephrine (belcher), not therapeutically equivalent to j0171, 0.1 mg | <1% | 19 | $74.58 |
| 88720 | <1% | 58 | $60.32 | |
| G0009 | Administration of pneumococcal vaccine | <1% | 33 | $58.27 |
| G0008 | Administration of influenza virus vaccine | <1% | 97 | $55.92 |
| J2010 | Injection, lincomycin hcl, up to 300 mg | <1% | 14 | $50.38 |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | <1% | 18 | $50.11 |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 224 | $48.46 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 13 | $47.60 |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 42 | $32.91 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 124 | $32.60 |
| 89055 | <1% | 15 | $27.41 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 152 | $23.66 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 219 | $23.03 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 37 | $21.70 |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | <1% | 47 | $20.21 |
| Q3014 | Telehealth originating site facility fee | <1% | 15 | $12.48 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 24 | $5.00 |
| 87102 | 0% | 13 | $0.00 | |
| 00840 | 0% | 165 | $0.00 | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | 0% | 17 | $0.00 |
| 87101 | 0% | 15 | $0.00 | |
| 99152 | 0% | 12 | $0.00 | |
| 88112 | 0% | 13 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 477 | $0.00 |
| 94010 | 0% | 14 | $0.00 | |
| 87206 | 0% | 27 | $0.00 | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 0% | 17 | $0.00 |
| 91307 | 0% | 12 | $0.00 | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | 0% | 29 | $0.00 |
| 1126F | 0% | 61 | $0.00 | |
| 88342 | 0% | 45 | $0.00 | |
| 87015 | 0% | 27 | $0.00 | |
| 87116 | 0% | 27 | $0.00 | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 42 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWRAY, DEAN (VICE PRESIDENT OF FINANCE)
| Provider | Location | Paid |
|---|---|---|
| Southern Ohio Medical Center | Portsmouth, OH | $10.54M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.